|
Gottlieb Speech Signals a Sea Change In FDA Drug Safety Strategy, Advocate Says
A senior FDA official’s speech urging the agency to pull back from requiring risk management plans as a part of the drug approval process signals a major change in the FDA’s thinking on drug safety, an industry observer says. This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives